Pfizer and BioNTech’s COVID-19 vaccine research started with multiple approaches—four shots on the messenger RNA goal. The partners have narrowed their choices to one for pivotal testing, and that candidate takes the same tack as other companies trying to address the novel coronavirus.

BNT162b2, the vaccine candidate that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) will advance to a Phase 2/3 study, is designed to get cells to produce the full spike protein of the novel coronavirus as a way to spark immunity. The choice is somewhat of a surprise. Earlier this month, the companies published preliminary Phase Read more »